BioPharmSignal logoBioPharmSignal

Biotech News

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

Fulgent Genetics, Inc. (FLGT)Fulgent Genetics, Inc.Company update

EL MONTE, Calif. --(BUSINESS WIRE)--Apr. 22, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be

Related news

FLGTFulgent Genetics, Inc.2026-10-15 20:05 EST

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

FLGTFulgent Genetics, Inc.2026-11-05 21:05 EST

Fulgent Reports Third Quarter 2026 Financial Results

IMCRImmunocore Holdings plc2026-10-29 13:00 EST

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

BNTXBioNTech2026-10-26 09:00 EST

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

BMYBMYBristol-Myers Squibb Company2026-10-19 10:59 EST

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

View all latest news

Fulgent Genetics, Inc.

Precision Medicine Business Fulgent Genetics operates a laboratory-services business alongside a therapeutic-development portfolio. The company aims to combine diagnostic capabilities with drug development to become an integrated precision-medicine organization. Laboratory Services Fulgent provides technical laboratory testing and...

Recent company news

FLGTFulgent Genetics, Inc.2026-11-05 21:05 EST

Fulgent Reports Third Quarter 2026 Financial Results

FLGTFulgent Genetics, Inc.2026-10-15 20:05 EST

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

FLGTFulgent Genetics, Inc.2026-07-30 20:05 EST

Fulgent Reports Second Quarter 2026 Financial Results

FLGTFulgent Genetics, Inc.2026-07-09 20:05 EST

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

FLGTFulgent Genetics, Inc.2026-06-01 23:00 EST

Fulgent Presents Updated FID-007 Data at ASCO 2026

Stock data

Close
18.66 USD
Market cap
531.09M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States